JP2008513367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513367A5 JP2008513367A5 JP2007531313A JP2007531313A JP2008513367A5 JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5 JP 2007531313 A JP2007531313 A JP 2007531313A JP 2007531313 A JP2007531313 A JP 2007531313A JP 2008513367 A5 JP2008513367 A5 JP 2008513367A5
- Authority
- JP
- Japan
- Prior art keywords
- apo2l
- antibody
- medicament according
- trail polypeptide
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 15
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60790904P | 2004-09-08 | 2004-09-08 | |
| US66655305P | 2005-03-30 | 2005-03-30 | |
| PCT/US2005/031907 WO2006029224A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513367A JP2008513367A (ja) | 2008-05-01 |
| JP2008513367A5 true JP2008513367A5 (enExample) | 2008-11-13 |
Family
ID=35788048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531313A Pending JP2008513367A (ja) | 2004-09-08 | 2005-09-07 | デスレセプターリガンド及びｃｄ２０抗体の使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090317384A1 (enExample) |
| EP (1) | EP1791864A2 (enExample) |
| JP (1) | JP2008513367A (enExample) |
| KR (1) | KR20070050950A (enExample) |
| AU (1) | AU2005282440A1 (enExample) |
| BR (1) | BRPI0515615A (enExample) |
| CA (1) | CA2577823A1 (enExample) |
| IL (1) | IL181316A0 (enExample) |
| MX (1) | MX2007002855A (enExample) |
| NO (1) | NO20071790L (enExample) |
| NZ (1) | NZ553174A (enExample) |
| RU (1) | RU2007112929A (enExample) |
| WO (1) | WO2006029224A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| GB0524316D0 (en) * | 2005-11-29 | 2006-01-04 | Medical Res Council | Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs) |
| EP2084530A2 (en) * | 2006-10-23 | 2009-08-05 | The UAB Research Foundation | Biomarkers for cancer sensitivity and uses thereof |
| EP2177230A4 (en) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| EP2473191B1 (en) * | 2009-09-04 | 2017-08-23 | XOMA Technology Ltd. | Antibody coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| MX2013012716A (es) * | 2011-05-03 | 2014-03-21 | Genentech Inc | Agentes de disociacion vascular y sus usos. |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) * | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| KR102532779B1 (ko) * | 2017-09-08 | 2023-05-16 | 한국생명공학연구원 | Ddias 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물 |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69533863T2 (de) * | 1994-02-04 | 2006-02-16 | Bio Merieux | MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen |
| KR101004174B1 (ko) * | 1995-06-29 | 2010-12-24 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| ATE362982T1 (de) * | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| NZ337795A (en) * | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| CA2287085A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| JPH11162958A (ja) * | 1997-09-16 | 1999-06-18 | Tokyo Electron Ltd | プラズマ処理装置及びその方法 |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| EP1401476A4 (en) * | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
| EP2348043A1 (en) * | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2 ligand variants and uses thereof |
| NZ533164A (en) * | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| WO2003039486A2 (en) * | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| US20060141561A1 (en) * | 2002-06-24 | 2006-06-29 | Kelley Robert F | Apo-2 ligand/trail variants and uses thereof |
-
2005
- 2005-09-07 NZ NZ553174A patent/NZ553174A/en not_active IP Right Cessation
- 2005-09-07 AU AU2005282440A patent/AU2005282440A1/en not_active Abandoned
- 2005-09-07 EP EP05794923A patent/EP1791864A2/en not_active Withdrawn
- 2005-09-07 RU RU2007112929/13A patent/RU2007112929A/ru not_active Application Discontinuation
- 2005-09-07 WO PCT/US2005/031907 patent/WO2006029224A2/en not_active Ceased
- 2005-09-07 MX MX2007002855A patent/MX2007002855A/es not_active Application Discontinuation
- 2005-09-07 KR KR1020077005374A patent/KR20070050950A/ko not_active Withdrawn
- 2005-09-07 BR BRPI0515615-7A patent/BRPI0515615A/pt not_active IP Right Cessation
- 2005-09-07 CA CA002577823A patent/CA2577823A1/en not_active Abandoned
- 2005-09-07 US US11/662,314 patent/US20090317384A1/en not_active Abandoned
- 2005-09-07 JP JP2007531313A patent/JP2008513367A/ja active Pending
-
2006
- 2006-10-03 US US11/542,528 patent/US20080044421A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181316A patent/IL181316A0/en unknown
- 2007-04-04 NO NO20071790A patent/NO20071790L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513367A5 (enExample) | ||
| ES2973858T3 (es) | Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R | |
| RU2007112929A (ru) | Способы применения лигандов рецептора смерти и антител к cd20 | |
| Li et al. | Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells | |
| US11779631B2 (en) | CD47 blockade therapy by HDAC inhibitors | |
| TW201641104A (zh) | Ｉｌ－１７抗體之醫藥產品及穩定之液體組合物 | |
| CN109789196A (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
| EP1921090A4 (en) | COMPOSITION OF GENETICALLY MODIFIED ANTIBODY | |
| JP2009519257A5 (enExample) | ||
| JP2008512479A5 (enExample) | ||
| JP2010518079A5 (enExample) | ||
| JP2015520188A5 (enExample) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20200237822A1 (en) | Compositions and methods for stimulating natural killer cells | |
| ES2860480T3 (es) | Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos | |
| Amini-Vaughan et al. | Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer | |
| US20250333522A1 (en) | Compositions and methods for treating pain in subjects with rheumatoid arthritis | |
| EP4268803A1 (en) | Stable antibody preparation, preparation method for same, and applications thereof | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| TW202225190A (zh) | 用於治療嗜中性球性皮膚病之抗-il-36r抗體 | |
| CN115666643A (zh) | 用于治疗异位性皮肤炎的抗il-36r抗体 | |
| AU2019235627A1 (en) | Improvements in CD47 blockade therapy by EGFR antibody | |
| JP2014526440A5 (enExample) | ||
| CN116406290A (zh) | 用于治疗慢性炎症性疼痛的抗il-36r抗体 | |
| TWI737000B (zh) | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 |